Deep learning-based measurement of echocardiographic data and its application in the diagnosis of sudden cardiac death.

Journal: Biotechnology & genetic engineering reviews
Published Date:

Abstract

This study aimed to evaluate the potential of deep learning applied to the measurement of echocardiographic data in patients with sudden cardiac death (SCD). 320 SCD patients who met the inclusion and exclusion criteria underwent clinical evaluation, including age, sex, BMI, hypertension, diabetes, cardiac function classification, and echocardiography. The diagnostic value of deep learning model was observed by dividing the patients into two groups: training group (n=160) and verification group (n=160), as well as two groups of healthy volunteers (n=200 for each group) during the same period. Logistic regression analysis showed that MLVWT, LVEDD, LVEF, LVOT-PG, LAD, E/e' were all risk factors for SCD. Subsequently, a deep learning-based model was trained using the collected images of the training group. The optimal model was selected based on the identification accuracy of the validation group and showed an accuracy of 91.8%, sensitivity of 80.00%, and specificity of 91.90% in the training group. The AUC value of the ROC curve of the model was 0.877 for the training group and 0.995 for the validation groups. This approach demonstrates high diagnostic value and accuracy in predicting SCD, which is clinically important for the early detection and diagnosis of SCD.

Authors

  • Lu Zhang
    Department of Computer Science and Engineering, The University of Texas at Arlington, Arlington, TX, United States.
  • Bohan Liu
    Medical Big Data Research Center, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China.
  • Sulei Li
    Department of cardiology, the Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.
  • Jing Wang
    Endoscopy Center, Peking University Cancer Hospital and Institute, Beijing, China.
  • Yang Mu
    Cardiovascular Department, the 6th Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Xuan Zhou
    Clinical Trial Institution, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315100, China.
  • Li Sheng
    Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Xiannongtan Street, Beijing 100050, China; Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Xiannongtan Street, Beijing 100050, China; Beijing Key Laboratory of Active Substances Discovery and Drug Ability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Xiannongtan Street, Beijing 100050, China; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Xiannongtan Street, Beijing 100050, China. Electronic address: shengli@imm.ac.cn.